Medical interpretation AI
No Barrier
No Barrier provides institution-purchased medical interpretation. Its terms allow deletion or anonymization and continuing derivative-data uses, while its security page makes broader deletion and no-repurposing promises. Patient alternatives and correction remain deployment-dependent.
Checklist assessment dated October 30, 2026. Independent confirmation is incomplete. Hugo has not personally verified this service.
Agency checklist · October 30, 2026
Constrains 2 of 12 yes
Document-based draft. Independent confirmation is incomplete. Hugo has not personally verified this service.
Assessed function: No Barrier AI medical interpretation (real-time speech-to-speech AI interpreter with visual term support and bilingual discharge notes) purchased by institutions and used directly with patients.
A no can mean missing documentation or institution-dependent control; it does not by itself establish harmful behavior. These categories are not clinical safety or product-quality ratings.
- Public documents do not establish actual product behavior.
- The independent review screened rules and selected evidence; it did not replicate all twelve answers for this tool.
See all twelve answers and their evidence
| Question | Answer | Evidence / review | Source and reasoning |
|---|---|---|---|
| 1. Told it is AI | No | deployer-dependent Not independently replicated | obtained any and all permissions, authorizations and/or informed consents from the patientsSource The Terms put patient consent on the customer. No No Barrier-provided notice to the patient is documented. |
| 2. Operator and model maker named | No | not-documented Not independently replicated | our proprietary AI Medical Interpreter platformSource Operator named: NoBarrier Inc. / No Barrier AI, Inc. (San Francisco). The maker of the underlying speech and translation models is not named in the pages read. 'Proprietary' is the Terms' wording for the platform. The Trust Center was linked but not read. |
| 3. Patient chooses to use it | No | deployer-dependent Not independently replicated | The care team selects the patient’s preferred languageSource Care team starts the session. Institution-purchased. |
| 4. Patient sets the task | No | not-documented Not independently replicated | Quotation not recorded; evidence repair pending. Source The care team sets the language and session. The patient does not set the purpose. |
| 5. Patient can decline or stop | Yes | documented Corrected after independent review; accepted by editor | You shall offer the patients the option of using this Platform or another methodSource Section 7.3 requires offering another method. This documents a patient choice, not tested equivalence of interpretation quality. |
| 6. Patient sees the AI output | Yes | documented Not independently replicated | As complex medical terms arise, the system displays visual aids helping patients understand conditions and procedures more clearly.Source The patient sees system-generated visual aids and hears the interpretation, per the vendor's product page (marketing). The bilingual discharge summary is also generated automatically. Vendor page, not a binding document. |
| 7. Patient can correct or challenge | No | not-documented Not independently replicated | Quotation not recorded; evidence repair pending. Source No route to correct or contest an interpretation is documented. |
| 8. Patient can get a copy | No | deployer-dependent Not independently replicated | you retain ownership rights in and to Your Information, and own the ResultsSource 'You' is the customer. The patient has no documented route. Content is deleted within 7 days by default. |
| 9. Patient can delete | No | deployer-dependent Not independently replicated | Every encounter's content is automatically deleted after 7 days, unless otherwise agreed with the customer.Source Automatic deletion, set with the customer. No patient-initiated deletion. The privacy policy says the customer is responsible for data subject rights for customer information, and it lets customers and site visitors request erasure of their own personal information. |
| 10. Training or sale does not override patient choice | No | documented Not independently replicated | on a perpetual basis, and provided Your Information is anonymized, de-identified or pseudonymized, for the purpose of generally enhancing the PlatformSource Terms Section 4 licenses anonymized Patient Records to No Barrier perpetually, with no patient opt-out. The Security page says 'We never train on, repurpose or sell your data'. I answered by the Terms and noted the conflict. |
| 11. Patient can run it or take it elsewhere | No | documented Not independently replicated | The Platform is licensed and not sold to you under this AgreementSource Vendor-hosted. No patient route to run it or move the function. |
| 12. No advertising or data business | No | documented Not independently replicated | you hereby agree to our collection, use, dissemination, sale, transfer, and exploitation of such Summary DataSource Terms Section 4 covers anonymous aggregated Summary Data, including 'sale'. The Privacy Policy also documents targeted advertising on the website. The Security page says it never sells data, which conflicts. |
Initial coding: Claude Sonnet helpers, compiled by Claude Opus 5.5 (Anthropic). Selective review and corrections: GPT-6 Astra (OpenAI). Editor: Hugo Campos. Acceptance of corrections is not product verification.
Checklist rules · Independent review and limitations · Later evidence follow-up
Earlier v1.3 assessment and control finding
Historical assessment under different rules. It does not set the current checklist zone.
Agency finding, before method v1.3
Mixed, institution-led language-access aid
Control axis not applicable: no patient-set purpose
Historical editorial placement, pre-method: 43. No longer shown on the control axis.
This profile has not yet been reviewed under the published method. Its finding and any number are editorial placements made before the method existed.
- Evidence
- Documentary review. Public sources only, no hands-on testing by HugoScore.
- Review status
- AI draft. No person has settled the findings.
Earlier evidence and assessment
The sections below preserve the earlier review. Its classifications and provenance are historical; the checklist above gives the current draft classification.
Earlier finding · Control axis not applicable: no patient-set purpose
Method v1.3. The control line is evidence for how the agency finding arose, not a quality score. Legacy editorial placement, pre-method: 43. Not comparable with v1.3 positions.
Mixed, institution-led language-access aid
No Barrier provides institution-purchased medical interpretation. Its terms allow deletion or anonymization and continuing derivative-data uses, while its security page makes broader deletion and no-repurposing promises. Patient alternatives and correction remain deployment-dependent.
Patient agency
How this tool changes agency
Visual explanation and bilingual notes may improve comprehension. Patient-accessible comparison with source speech, qualified review of important summaries and a durable correction route remain unestablished by this pass.
Patient notice, refusal experience, interpreter escalation, deployment-specific BAA and derivative-data handling were not observed.
Patient agency assessment
Who sets and changes the goal?
Language access can let patients express goals and challenge care decisions. The organization selects and configures the platform. A contractual alternative is meaningful, but it does not establish that a patient can trigger it promptly or correct a disputed translation afterward.
What can the patient understand, question, or do?
Visual explanation and bilingual notes may improve comprehension. Patient-accessible comparison with source speech, qualified review of important summaries and a durable correction route remain unestablished by this pass.
Can the patient evaluate the conditions of use?
The concrete distinction between deletion and anonymization matters to informed participation. Broad no-repurposing messaging does not explain surviving derivative-data permissions or which agreement controls a particular encounter.
Text findings
Conditions of use
Published controls and their limits
The concrete distinction between deletion and anonymization matters to informed participation. Broad no-repurposing messaging does not explain surviving derivative-data permissions or which agreement controls a particular encounter.
What remains unknown?
Not tested or not established
Patient notice, refusal experience, interpreter escalation, deployment-specific BAA and derivative-data handling were not observed.
Who evaluated this?
AI-assisted public-source draft
Vendor statements describe published conditions, not independently verified behavior. No clinical, security, accessibility, or legal validation is claimed. Earlier evidence remains dated in the report and history.
Sources checked
- https://www.nobarrier.ai/legal/terms-of-service
- https://www.nobarrier.ai/security
- https://www.nobarrier.ai/ai-interpreting
Source-specific findings and retrieval limitations are recorded in the full report.
Earlier review provenance
Criteria
CAIHL-derived HugoScore framework and September 7 qualitative review priorities. Draft v1.2 numerical anchors remain unadopted.
Reviewer
AI-assisted public-source reassessment prepared in OpenAI Codex.
AI / model
OpenAI Codex / GPT-6
Human review
Hugo Campos authorized publication of these AI-assisted draft reassessments on September 8, 2026. This does not claim comprehensive human verification of every finding.
Review date
2026-09-08
Limitations
Patient notice, refusal experience, interpreter escalation, deployment-specific BAA and derivative-data handling were not observed. No live product use, patient-data upload, account creation, code audit, clinical evaluation, or independent implementation validation.
Earlier review method
Focused public-source reassessment using CAIHL: patient authority, critical capacity, and informed control. Existing evidence plus one focused primary-source pass and at most one targeted follow-up. No live product testing. Numerical scores remain provisional editorial placements, not a new calculation.
Document-based draft · Medium for published conditions, low for encounter-level implementation (AI-assisted draft)